0
Diffuse Lung Disease |

GAP Index for Idiopathic Pulmonary Fibrosis in a Portuguese Cohort

Margarida Redondo, MD; Natalia Melo, MD; Diogo Costa, PhD; Patricia Mota, MD; Antonio Morais, MD
Author and Funding Information

Centro Hospitalar de São João, Porto, Portugal


Chest. 2014;145(3_MeetingAbstracts):255A. doi:10.1378/chest.1825339
Text Size: A A A
Published online

Abstract

SESSION TITLE: ILD

SESSION TYPE: Slide Presentations

PRESENTED ON: Saturday, March 22, 2014 at 12:15 PM - 01:15 PM

PURPOSE: Patients with Idiopathic Pulmonary Fibrosis (IFP) demonstrate widely variable clinical courses and survival. Thus, predicting prognosis in patients with IPF is a challenge for clinicians. Multidimensional GAP (gender, age and 2 lung physiology variables [FVC and DLCO]) index and staging system was developed to predict mortality in IPF. The purpose of this study is to use GAP multidimensional index in IPF patients observed in recent years in our Interstitial Lung Diseases (ILD) outpatient clinic and understand if our results go in line with the published data.

METHODS: Eighty two patients with IPF diagnosis according to the ATS/ERS criteria were included. Medical records were retrospectively analyzed. Patients were characterized by clinical and physiological findings, at the time of diagnosis. Patients were censored at death or lung transplant and classified according to the 3 stages of the GAP index. Hazard Ratios (HR), 95% Confidence intervals (95%CI) were computed using univariate Cox regression models to estimate the risk of being classified in stages II and III after 12, 24, 36, 48 and 60 months of follow-up.

RESULTS: From eighty two patients included, 72% were males, with a mean age at diagnosis of 67.2±10.6 years old. Forty-six deaths and 6 lung transplantations occurred. FVC and DLCO at diagnosis were 74.8±17.5% and 45.7±17.8%, respectively. According to the stages of the GAP index: 36 patients were classified in stage I, 39 patients in stage II and 7 patients in stage III. Median follow-up was 29.1 months (range, 2 to 123 months). An increase in the HR (95%CI) estimates was observed according to GAP stages and follow-up time. Compared to stage I patients, at 60 months, HR (95%CI) for stage II and stage III patients were 1.37 (0.72-2.59) and 3.46 (1,42-8.47).

CONCLUSIONS: In this Portuguese sample, the GAP index was useful to classify patient according to prognosis severity. Larger samples and adjustment for known confounders might be needed to accurately test this index prognostic value.

CLINICAL IMPLICATIONS: GAP index can be used to properly identify the disease severity of an IPF patient.

DISCLOSURE: The following authors have nothing to disclose: Margarida Redondo, Natalia Melo, Diogo Costa, Patricia Mota, Antonio Morais

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543